--- title: "BioXcel Therapeutics (BTAIQ) stock and investor profile" url: "https://aibio.space/companies/bioxcel-therapeutics-btaiq/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BioXcel Therapeutics, Inc. (OTC: BTAIQ), United States. Listing facts, related biotech companies and news on aibio.space." --- BTAIQ BioXcel Therapeutics, Inc. OTC · United States # BioXcel Therapeutics (BTAIQ) news Debt Financing · 2026-07-06 ## [BioXcel amends its credit agreement and forms a strategic process committee](https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/) The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. ## Latest BioXcel Therapeutics news 1. 2026-05-15 Company Updates [BioXcel reports first quarter 2026 results and engages MTS Health Partners](https://aibio.space/news/bioxcel-reports-first-quarter-2026-results-engages-mts-health-partners/) The company said the FDA accepted its IGALMI at-home sNDA with a November 14, 2026 PDUFA date, and that it is reviewing strategic options. First quarter net loss was $12.7 million. ## BioXcel Therapeutics at a glance - **Ticker**: BTAIQ - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $12.8 million ### Related companies - [Ceribell](https://aibio.space/companies/ceribell/) NASDAQ: CBLL - [ALPHA PRO TECH LTD](https://aibio.space/companies/alpha-pro-tech/) NYSE: APT - [RETRACTABLE TECHNOLOGIES INC](https://aibio.space/companies/retractable-technologies/) NYSE: RVP - [UFP TECHNOLOGIES INC](https://aibio.space/companies/ufp-technologies/) NASDAQ: UFPT - [RetinalGenix Technologies](https://aibio.space/companies/retinalgenix-technologies/) OTC: RTGN - [MANNATECH INC](https://aibio.space/companies/mannatech/) NASDAQ: MTEX - [Nautilus Biotechnology](https://aibio.space/companies/nautilus-biotechnology/) NASDAQ: NAUT - [OPKO HEALTH, INC.](https://aibio.space/companies/opko-health/) NASDAQ: OPK ### Also on OTC - [RepliCel Life Sciences](https://aibio.space/companies/replicel-life-sciences/) REPCF - [CV Sciences](https://aibio.space/companies/cv-sciences/) CVSI - [Allstar Health Brands](https://aibio.space/companies/allstar-health-brands/) ALST - [Hypha Labs](https://aibio.space/companies/hypha-labs/) FUNI - [VITASPRING BIOMEDICAL CO. LTD.](https://aibio.space/companies/vitaspring-biomedical/) VSBC - [OSR Health](https://aibio.space/companies/osr-health/) OSRH ## BioXcel Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$642,000](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | [$2.3 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | | Research and development | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | [$30.4 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | | Net income (loss) | [-$69.9 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | [-$59.6 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | | Cash from operations | [-$57.6 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | [-$72.0 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | | Cash and equivalents | [$28.4 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/) | [$29.9 million](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioXcel Therapeutics What is the ticker symbol of BioXcel Therapeutics? BioXcel Therapeutics, Inc. trades under the ticker BTAIQ on OTC. Where is BioXcel Therapeutics listed? BioXcel Therapeutics, Inc. is listed on OTC. Which country or territory is BioXcel Therapeutics listed under? Our directory records BioXcel Therapeutics, Inc. under United States. Does aibio.space cover BioXcel Therapeutics? aibio.space lists BioXcel Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was BioXcel Therapeutics's revenue last year? $642,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is BioXcel Therapeutics profitable? BioXcel Therapeutics, Inc. reported a net loss of $69.9 million for the fiscal year ended Dec 31, 2025, and used $57.6 million of cash in operations, per its annual report to the SEC. How much does BioXcel Therapeutics spend on research and development? $30.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does BioXcel Therapeutics have? $12.8 million in cash at Jun 30, 2026, per its 10-Q. What is the latest BioXcel Therapeutics (BTAIQ) stock news? Our latest story on BioXcel Therapeutics, dated Jul 6, 2026: "BioXcel amends its credit agreement and forms a strategic process committee". The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. [Source](https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/). Does BioXcel Therapeutics have debt, a term loan or convertible notes? Our latest debt story, dated Jul 6, 2026: "BioXcel amends its credit agreement and forms a strategic process committee". The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. [Source](https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/). How long will BioXcel Therapeutics's cash last? From our story of May 15, 2026: The release gives no cash runway estimate, and approval of the at-home label is not assured. [Source](https://aibio.space/news/bioxcel-reports-first-quarter-2026-results-engages-mts-health-partners/). How can I follow BioXcel Therapeutics (BTAIQ) news? Press Follow on this page to add BioXcel Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming BioXcel Therapeutics so far, in Company Updates, Debt Financing. ## Investor discussion: BioXcel Therapeutics Members talk about BioXcel Therapeutics (BTAIQ). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioXcel Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-30 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1720893/000110465926120737/tm2624733d2_ex99-1.htm) 2. 2026-09-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.03,3.01). [Source](https://www.sec.gov/Archives/edgar/data/1720893/000110465926104106/tm2624539d1_8k.htm) 3. 2026-08-28 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,1.03). [Source](https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/tm2624233d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:BTAIQ on TradingView](https://www.tradingview.com/symbols/OTC-BTAIQ/). ## Listing details BioXcel Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker BTAIQ, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioXcel Therapeutics, Inc. - **Ticker**: BTAIQ - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bioxcel-therapeutics-btaiq/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioXcel Therapeutics (BTAIQ) stock and investor profile", 2026-10-31, https://aibio.space/companies/bioxcel-therapeutics-btaiq/